High-Dose Therapy and Autologous Peripheral-Blood Stem-Cell Transplantation As Salvage Treatment for HIV-Associated Lymphoma in Patients Receiving Highly Active Antiretroviral Therapy
Authors:
- Alessandro ReARAlessandro Re
- Chiara CattaneoCCChiara Cattaneo
- Mariagrazia MichieliMMMariagrazia Michieli
- Salvatore CasariSCSalvatore Casari
- Michele SpinaMSMichele Spina
- Maurizio RupoloMRMaurizio Rupolo
- Bernardino AllioneBABernardino Allione
- Annamaria NosariANAnnamaria Nosari
- Clara SchiantarelliCSClara Schiantarelli
- Mariagrazia ViganòMVMariagrazia Viganò
- Immacolata IzziIIImmacolata Izzi
- Piero FerremiPFPiero Ferremi
- 1 December 2003
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (23) , 4423-4427
Abstract
Purpose: High-dose therapy (HDT) and peripheral-blood stem-cell transplantation (PBSCT) in HIV-associated lymphoma (HIV-Ly) has been recently reported in selected patients. We describe the results of a multi-institutional program of HDT and PBSCT as salvage therapy in HIV-Ly responsive to highly active antiretroviral therapy (HAART) in unselected patients. Patients and Methods: Patients with resistant or relapsed HIV-Ly after first-line chemotherapy (CT) underwent PBSC collection after a course of second-line CT or cyclophosphamide and granulocyte colony-stimulating factor. Patients with chemotherapy-sensitive disease received carmustine, etoposide, cytarabine, and melphalan (BEAM regimen) and PBSC reinfusion. Effective HAART was maintained during the entire program. Results: Sixteen consecutive patients entered the program. Adequate collection of PBSC was obtained in 80% of patients (median CD34+ cells 6.8 × 106/kg). Three patients had early progression. Ten patients (62%) received PBSCT with prompt engraftment in all patients (neutrophils and platelet engraftment after a median of 10 days [range, 8 to 10 days] and 13 days [range, 8 to 18 days], respectively). No patients died as a result of opportunistic or other infections or treatment-related complications. Eight of nine assessable patients achieved complete remission (one patient after radiotherapy for residual disease) and one patient achieved partial remission. Two patients experienced relapse and died at +10 and +14 months. Six patients are alive and disease free at a median of 8 months after transplantation. Conclusion: Our data confirm that HDT plus PBSCT is feasible and active as salvage therapy in HIV-Ly on a multi-institutional basis and in unselected HAART-responding patients. HIV infection should no longer preclude the opportunity of HDT in patients with lymphoma.Keywords
This publication has 16 references indexed in Scilit:
- Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infectionBlood, 2002
- Prognostic Factors in the Treatment of Human Immunodeficiency Virus-Associated Non-Hodgkin’s Lymphoma2002
- Infusional CDE with Rituximab for the Treatment of Human Immunodeficiency Virus-Associated Non-Hodgkin’s Lymphoma: Preliminary Results of a Phase I/II Study2002
- Autologous stem cell transplantation for HIV-associated lymphomaBlood, 2001
- High-Dose Cytosine–Arabinoside and Cisplatin Regimens as Salvage Therapy for Refractory or Relapsed AIDS-Related Non-Hodgkin's LymphomaJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- High-dose therapy and autologous haematopoietic stem-cell transplantation for HIV-1-associated lymphomaThe Lancet, 2000
- Intensive Chemotherapy (LNHIV-91 Regimen) and G-CSF for HIV Associated Non-Hodgkin's LymphomaLeukemia & Lymphoma, 2000
- Second-line chemotherapy in human immunodeficiency virus-related non-Hodgkin's lymphoma: Evidence of activity of a combination of etoposide, mitoxantrone, and prednimustine in relapsed patientsCancer, 1996
- Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1995
- Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trialThe Lancet, 1993